drug
rotigotine ER
Marketedupdated 3mo agoby UCB SA
Approvedcommunity read0 votes
indications
investigational
Parkinson's Disease
all catalysts(0)
nothing on the calendar yet
Trials studying rotigotine ER
- N/AAdhesion and Safety of Rotigexole Compared to Neupro®
- phase4Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease
- phase2Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease
- phase3A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome
- phase3A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 1, 2027
~1.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (24)
- Mar 1, 2032formulationUS 9925150
- Mar 1, 2032formulationUS 9925150
- Mar 1, 2032formulationUS 9925150
- Mar 1, 2032formulationUS 9925150
- Mar 1, 2032formulationUS 9925150
- Mar 1, 2032formulationUS 9925150
- Dec 22, 2030formulationUS 101305894.4y
- Dec 22, 2030formulationUS 101305894.4y
- Dec 22, 2030formulationUS 101305894.4y
- Dec 22, 2030formulationUS 101305894.4y
- Dec 22, 2030formulationUS 101305894.4y
- Dec 22, 2030formulationUS 101305894.4y
- Dec 22, 2030formulationUS 103501744.4y
- Dec 22, 2030formulationUS 103501744.4y
- Dec 22, 2030formulationUS 103501744.4y
- Dec 22, 2030formulationUS 103501744.4y
- Dec 22, 2030formulationUS 103501744.4y
- Dec 22, 2030formulationUS 103501744.4y
- Sep 1, 2027formulationUS 82469791.0y
- Sep 1, 2027formulationUS 82469791.0y
- Sep 1, 2027formulationUS 82469791.0y
- Sep 1, 2027formulationUS 82469791.0y
- Sep 1, 2027formulationUS 82469791.0y
- Sep 1, 2027formulationUS 82469791.0y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 5m ago
Found something off?
comments(0)
5-min edit window · permanent after that